Patents Issued in April 15, 2021
-
Publication number: 20210106675Abstract: A novel attenuated vaccinia virus GAB-1 and its use in treatment of papillomavirus lesions. In preferred embodiments, the Lederle-Chorioallantoic strain of vaccinia virus is serially passaged in chicken embryo-fibroblast (CEF) cells by at least 100 passages. Surprisingly, GAB-1 is highly immunogenic after serial passaging, while being less virulent and safe to use without side effects. Experimentation has found that GAB-1 is much more immunogenic than other strains of vaccinia virus, including Western Reserve (WR) and modified Vaccinia Ankara (MVA). GAB-1 can be used safely in humans for treating tumorous lesions caused by human papillomavirus (HPV).Type: ApplicationFiled: October 10, 2019Publication date: April 15, 2021Inventor: Ricardo Rosales Ledezma
-
Publication number: 20210106676Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.Type: ApplicationFiled: October 13, 2020Publication date: April 15, 2021Inventors: Martin BACHMANN, Gary JENNINGS, Thomas KÜNDIG, Gabriela SENTI, Franziska ZABEL
-
Publication number: 20210106677Abstract: A method of eliciting immune responses using synthetic antigens involves generating a substitute antigen configured for a foreign molecule, generating a synthetic high affinity ligand molecule (SHAL) comprising at least one ligand configured to bind to an antigen presenting cell (APC) and at least one ligand specifically configured to bind with the substitute antigen, combining the SHAL with the substitute antigen through a chemical reaction forming an antigen presenting complex, introducing the antigen presenting complex to a user without an immune response to the foreign molecule.Type: ApplicationFiled: November 13, 2018Publication date: April 15, 2021Applicant: MatSfide, Inc.Inventor: Michael McElfresh
-
Publication number: 20210106678Abstract: Disclosed is an immunity-inducing agent having excellent ease of production and high immunostimulatory activity, the immunity-inducing agent comprising, as an active component, a polynucleotide/peptide conjugate in which an antigenic peptide is covalently bound to a single-stranded polynucleotide or polynucleotide derivative. Also disclosed is a pharmaceutical composition comprising said immunity-inducing agent.Type: ApplicationFiled: March 20, 2018Publication date: April 15, 2021Applicant: The University of KitakyushuInventors: Shinichi Mochizuki, Kazuo Sakurai, Hiromi Morishita
-
Publication number: 20210106679Abstract: The present invention relates to a vaccine composition V comprising a peptidic entity A comprising one or more sequence motifs A1 of the sequence RR-X1a-X1b-L (SEQ ID NO: 23) wherein X1a is a hydrophobic amino acid moiety and X1b is a peptide bond or a hydrophobic amino acid moiety, or an analogue thereof, an antigen of interest B and silica particles C embracing A and B. Further, the present invention relates to the peptidic entity A usable for such purpose and pharmaceutical and non-pharmaceutical uses of the vaccine composition V.Type: ApplicationFiled: April 19, 2018Publication date: April 15, 2021Applicant: UNIVERSITÄT WIENInventors: Christian Friedrich Wilhelm Becker, Meder Kamalov
-
Publication number: 20210106680Abstract: The present invention is intended to provide an adjuvant having high safety to living bodies and an action to sufficiently reinforce immune function, and a vaccine comprising the adjuvant. Specifically, the present invention relates to 34 novel adjuvant candidate compounds, which have been identified by screening 145 food additives and 51 injection additives, using, as indicators, an increase in the antibody titer against influenza virus and a protective effect against infection with influenza virus, and then selecting those having the function of increasing the antiviral antibody titer in blood and the protective effect against viral infection. In addition, the present invention also relates to a vaccine comprising these adjuvant candidate compounds.Type: ApplicationFiled: March 26, 2019Publication date: April 15, 2021Applicant: The University of TokyoInventors: Yoshihiro Kawaoka, Huapeng Feng, Tokiko Watanabe, Makoto Yamashita
-
Publication number: 20210106681Abstract: The present invention is situated in the field of mineral micro-particles selected from the list consisting of aluminum hydroxide, aluminum phosphate, amorphous aluminium hydroxyphosphate and calcium phosphate micro-particles. More particularly, the invention provides organically-derivatized mineral micro-particles, uses thereof, and methods of preparing the same.Type: ApplicationFiled: April 10, 2019Publication date: April 15, 2021Applicant: Croda International PlcInventors: Laurent Duroux, Erik Lindblad
-
Publication number: 20210106682Abstract: A catheter package and method of use which serve to straighten a curved catheter shaft. The straightening of the catheter shaft may be accomplished by passing the shaft through a pathway that bends the catheter in the opposite direction of the curvature imparted to the catheter shaft. The catheter shaft pathway may incorporate various shaped bumps, ridges, pins or rollers or other features which assist in straightening the shaft.Type: ApplicationFiled: December 21, 2020Publication date: April 15, 2021Inventors: Edward H. Cully, James L. Goepfrich, William G. Hardie, Raymond P. Torrez
-
Publication number: 20210106683Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.Type: ApplicationFiled: November 13, 2018Publication date: April 15, 2021Inventors: Sandrine DURRAN, Andrew Jeffrey YATES
-
Publication number: 20210106684Abstract: The present invention is the creation of stable boron isotope (10B) containing nanosilica particles composing of amino acids, amino-oligosaccharides, and oligopeptides appropriate to the improvement of drug delivery system (DDS) function of delivering more boron to tumors selectively to facilitate the efficacy of boron neutron capture therapy (BNCT).Type: ApplicationFiled: September 19, 2018Publication date: April 15, 2021Applicant: DYNAMIC SCIENCE CORPORATIONInventors: Hitoshi HORI, Ken TOKUNAGA, Masao TAKAHASHI
-
Publication number: 20210106685Abstract: The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.Type: ApplicationFiled: December 23, 2020Publication date: April 15, 2021Inventors: Michael AVEN, Balazs ALBRECHT, Benjamin FRANZMANN, Matthias HAUSMANN, Janine LAMAR, Ingo LANG
-
Publication number: 20210106686Abstract: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.Type: ApplicationFiled: May 8, 2020Publication date: April 15, 2021Applicant: Eagle Pharmaceuticals, Inc.Inventor: Srikanth Sundaram
-
Publication number: 20210106687Abstract: Bolaamphiphilic compounds are provided according to formula I: where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering imaging agents into animal or human brain.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Inventors: Charles LINDER, Eliahu HELDMAN, Sarina GRINBERG
-
Publication number: 20210106688Abstract: This invention provides compounds that have spirocyclic E3 Ubiquitin Ligase targeting moieties (Degrons), which can be used as is or linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.Type: ApplicationFiled: May 22, 2020Publication date: April 15, 2021Applicant: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Kiel Lazarski, Ryan E. Michael
-
Publication number: 20210106689Abstract: A molecule comprising a saccharide bound via an O-glycosidic bond to a hydroxyl group of a toxic payload molecule is disclosed. An antibody-drug conjugate comprising an antibody covalently bound to a toxic payload molecule, optionally via a linker group, and a saccharide bound via an O-glycosidic bond to a hydroxyl group of the toxic payload molecule is further disclosed.Type: ApplicationFiled: November 4, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Tero Satomaa, Filip S. Ekholm
-
Publication number: 20210106690Abstract: A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently a therapeutic agent having a molecular weight ?5 kDa. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.Type: ApplicationFiled: January 23, 2020Publication date: April 15, 2021Inventors: Aleksandr V. YURKOVETSKIY, Mao YIN, Timothy B. LOWINGER, Joshua D. THOMAS, Charles E. HAMMOND, Cheri A. STEVENSON, Natalya D. BODYAK, Patrick R. CONLON, Dmitry R. GUMEROV
-
Publication number: 20210106691Abstract: The present disclosure relates to materials and methods of conjugating a water soluble polymer to a therapeutic protein.Type: ApplicationFiled: October 5, 2020Publication date: April 15, 2021Inventors: Juergen Siekmann, Alfred Weber, Hanspeter Rottensteiner, Peter Turecek
-
Publication number: 20210106692Abstract: The present invention relates to a conjugate represented by the formula [D-L-Y—(CH2)n-]mP-T wherein T is a protein; P is a polymer selected from the group consisting of dextran, mannan, pullulan, hyaluronic acid, hydroxyethyl starch, chondroitin sulphate, heparin, heparin sulphate, polyalkylene glycol, Ficoll, polyvinyl alcohol, amylose, amylopectin, chitosan, cyclodextrin, pectin and carrageenan, or a derivative thereof; m is at least 1; n is in the range of 1 to 10; each Y is independently selected from the group consisting of S, NH and 1,2,3-triazolyl, wherein 1,2,3-triazolyl is optionally substituted; each L is independently absent or comprises a linker group covalently joining D and Y; and each D is a payload molecule.Type: ApplicationFiled: September 22, 2020Publication date: April 15, 2021Applicant: Glykos Finland OyInventors: Jari Helin, Juhani Saarinen, Filip S. Ekholm, Anne Leppanen
-
Publication number: 20210106693Abstract: The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: ApplicationFiled: November 10, 2020Publication date: April 15, 2021Inventors: Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
-
Publication number: 20210106694Abstract: The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.Type: ApplicationFiled: December 20, 2018Publication date: April 15, 2021Applicant: Ontario Institute for Cancer Research (OICR)Inventors: Rima Al-awar, Ahmed Mamai
-
Publication number: 20210106695Abstract: The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles.Type: ApplicationFiled: October 13, 2020Publication date: April 15, 2021Inventors: Satya PRAKASH, Meenakshi MALHOTRA
-
TISSUE SPECIFIC MARKERS FOR PREOPERATIVE AND INTRAOPERATIVE LOCALIZATION AND VISUALIZATION OF TISSUE
Publication number: 20210106696Abstract: Surgeons may face the difficulty of preoperatively selecting the location for making an incision and intraoperatively identifying and differentiating targeted tissue for removal or for identification so that it is not removed along with neighboring or non-target tissue or so that neighboring or non-target tissue is not nicked, harmed, or removed accidentally. A tissue specific marker can include an aptamer or an affimer configured to bind to a pre-selected target tissue and one or more indicator elements coupled with the aptamer or the affimer. The one or more indicator elements produce a signal thereby allowing identification of the target tissue in a preoperative and operative manner.Type: ApplicationFiled: May 19, 2020Publication date: April 15, 2021Applicant: Invuity, Inc.Inventors: Dennise DALMA-WEISZHAUSZ, Alex VAYSER, James BREDENKAMP -
Publication number: 20210106697Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.Type: ApplicationFiled: October 15, 2020Publication date: April 15, 2021Applicant: NORTHWESTERN UNIVERSITYInventors: Evan A. Scott, Guillermo A. Ameer, Jacqueline A. Burke, Helena Freire Haddad
-
Publication number: 20210106698Abstract: The present invention relates to a MRI contrast agent for a liver cancer-specific imaging diagnosis including manganese silicate which releases manganese ion (Mn2+) under acidic conditions, and a method of characterizing liver tissue using the MRI contrast agent. In a relatively short time, T1-weighted images show different patterns depending on the tissue-specificity such as vascularity, cell density, mitochondrial activity, hepatocellular affinity and the like in normal liver tissues and lesion liver tissues (especially hepatic tumors), and thus, the disease-specific characteristics of liver cancers can be analyzed at appropriate times by analyzing the T1-weighted images. It is expected to be very useful for differentiating the liver cancer types or evaluating the therapeutic effect. Furthermore, it is expected to be useful for diagnosing the diseases occurring in organs other than liver based on the tissue-specificity.Type: ApplicationFiled: March 30, 2018Publication date: April 15, 2021Inventors: Won Jae LEE, Jung Hee LEE, Moon Sun JANG, in Su LEE, Jin Goo KIM
-
Publication number: 20210106699Abstract: A composition includes a plurality of stabilized nanobubbles and/or microbubbles. Each nanobubble and/or microbubble has a lipid membrane that defines at least one internal void, which includes at least one gas, the membrane including a plurality of lipids, an edge-activator, which is incorporated between lipids of the membrane and enhances the flexibility of the nanobubbles and/or microbubbles, and a membrane stiffener, which is incorporated on an outer surface of the membrane and enhances the membranes resistance to tearing.Type: ApplicationFiled: March 29, 2019Publication date: April 15, 2021Inventors: Agata Exner, Al de Leon, Reshani PERERA, Pinunta Tayacharn
-
Publication number: 20210106700Abstract: Disclosed herein is a fractionated dosing regimen of 131I-labeled 18-(p-iodo-phenyl)octadecyl phosphocholine for the treatment of cancer.Type: ApplicationFiled: April 10, 2019Publication date: April 15, 2021Inventor: Jarrod Longcor
-
Publication number: 20210106701Abstract: The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to which a radioactive metal-coupled chelator is structurally coupled and to which an aryl group that can additionally bind to PSMA protein is coupled. Coupling between the glutamine-urea-lysine compound and the chelator includes a polar spacer so as to serve the role of reducing in vivo nonspecific coupling and exhibit an effect of being rapidly removed from vital organs, but not from prostate cancer. These characteristics lower the radiation exposure, which is caused by a therapeutic radioisotope-coupled compound, to normal tissue and organs, and thus reduce side effects. In addition, a compound that contains a phenyl group having a coupling force with albumin has an increased residence time in the blood, thereby becoming more accumulated in prostate cancer.Type: ApplicationFiled: March 29, 2019Publication date: April 15, 2021Inventors: Dae Yoon CHI, Byoung Se LEE, So Young CHU, Hyeon Jin JEONG, Min Hwan KIM, Kyo Chul Lee, Yong Jin Lee
-
Publication number: 20210106702Abstract: Provided is a new boron isotope (10B) tracing drug which can exhibit wide-area molecular-targeting function and stereotactic destructive power. The invented boron isotope (10B) tracing drug has higher selective tumor-targeting and tumor-accumulating pharmacokinetic functions appropriate for neutron beam dynamic therapy (NBDT) and boron neutron capture therapy (BNCT).Type: ApplicationFiled: September 19, 2018Publication date: April 15, 2021Applicant: DYNAMIC SCIENCE CORPORATIONInventors: Hitoshi HORI, Ken TOKUNAGA, Masao TAKAHASHI
-
Publication number: 20210106703Abstract: The present invention relates to a combination of radioimmunoconjugates and a protein or molecule capable of leading to progression of the cell cycle through the G2/M checkpoint, a protein or molecule capable of inhibiting progression through Mitosis, a protein or molecule which is a BCL2 inhibitor, or a protein or molecule which is a PARP inhibitor, for use as a medicament. The medicament may be against Non-Hodgkin's lymphoma (NHL).Type: ApplicationFiled: November 21, 2018Publication date: April 15, 2021Inventors: Jean Pierre Pouget, Alexandre Pichard, Randi Syljuåsen, Gro Elise Rødland, Helen Heyerdahl, Sebastian Patzke, Jostein Dahle, Ada Repetto-Llamazares, Marion Masita Malenge
-
Publication number: 20210106704Abstract: An illustrated view of an exemplary sanitizing system for sanitizing medical equipment is presented. The sanitizing system is useful for sanitizing medical equipment, such as stethoscopes, of harmful and often times life-threatening pathogens such as MRSA and C-DIFF. The sanitizing system provides a chemical free sanitization while being easy to use and efficient. The sanitizing system produces a quick and easy way to sanitize medical equipment and thereby prevent infectious contaminants to both medical personnel and patients. The sanitizing system can be used in hospital settings, doctor's offices, clinics, ambulances, etc.Type: ApplicationFiled: October 15, 2019Publication date: April 15, 2021Inventors: Clifton Schermerhorn, Brock Schermerhorn, Barry Lyou
-
Publication number: 20210106705Abstract: The invention relates to an assembly and a method for completely sterilizing at least one object. For this purpose, a chamber is provided in which the object is sterilized. A plasma system for producing reactive species is associated with the chamber. A conveying means is arranged in such a way that a circulation mass flow leads through the plasma system and over the at least one object through the chamber and back to the conveying means. An outlet (8) is fluidically associated with the chamber such that an effective mass flow (8W) can be led out of the chamber.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Inventor: Stefan Nettesheim
-
Publication number: 20210106706Abstract: An endoscope reprocessor includes a bottle connecting instrument and a nozzle. The bottle connecting instrument includes a first advancing and retracting member which shuts off a first flow path at a first position and opens the first flow path at a second position; a first fitting member; and a first retaining member which retains the first advancing and retracting member. The nozzle includes a second advancing and retracting member which shuts off the nozzle at a third position and opens the nozzle at a forth position, a second fitting member to be fitted with the first fitting member, and a second retaining member which retains the second advancing and retracting member.Type: ApplicationFiled: December 23, 2020Publication date: April 15, 2021Applicant: OLYMPUS CORPORATIONInventors: Hideto ONISHI, Eiri SUZUKI, Yumiko AWAU
-
Publication number: 20210106707Abstract: Embodiments of the present disclosure relate to systems and methods for the application of vaporized chemicals in the sterilization of medical products. For example, embodiments of the present disclosure may relate to systems and methods for the terminal sterilization of medical products using vaporized hydrogen peroxide (VHP). Embodiments of the present disclosure may relate to, e.g., systems and methods for the terminal sterilization of medical products, such as pre-filled syringes (PFS).Type: ApplicationFiled: December 21, 2020Publication date: April 15, 2021Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Philip Stephen SHODDER
-
Publication number: 20210106708Abstract: One aspect of the present disclosure can include a thermoresponsive nanocomposite for disrupting or preventing biofilm formation. The nanocomposite can include at least one polymer, one or more D-amino acids, and one or more energy-actuatable particles. The nanocomposite can have a first viscosity at about room temperature and, when exposed to about physiological temperature, obtains a second viscosity that is greater than the first viscosity. Application of energy to the nanocomposite from an energy source can excite the one or more energy-actuatable particles to cause localized heat release from the nanocomposite.Type: ApplicationFiled: March 21, 2019Publication date: April 15, 2021Inventors: Anna Cristina S. SAMIA, Salvatore J. FRANGIAMORE, Carlos A. HIGUERA RUEDA, Alison K. KLIKA, Wael K. BARSOUM
-
Publication number: 20210106709Abstract: A sterilization container for sterilizing medical instruments that includes a body defining an interior volume and a lid connected to the body and configured to seal the interior volume between the lid and the body. The lid includes an exterior filter structure including a first plurality of ridges and a first plurality of troughs formed between the first ridges. The container includes a filter assembly connected to the lid and including an interior filter structure including a second plurality of ridges and a second plurality of troughs formed between the second ridges. The first plurality of ridges of the exterior filter structure are interposed between the second plurality of ridges of the interior filter structure. The exterior and interior filter structures are configured to form longitudinal channels positioned between the lid and filter assembly to define a rectangular tortuous filter path that inhibits ingress and egress from the interior volume.Type: ApplicationFiled: October 9, 2020Publication date: April 15, 2021Applicant: CareFusion 2200, Inc.Inventors: Jason Cartwright, Brandon Toth, Benjamin Hopwood, Bradley Thomas Williams, Andrew VanDeWeghe, Atif Yardimci
-
Publication number: 20210106710Abstract: An antibacterial air freshening product for an interior environment. The product includes a container containing 1 ml to 50 ml of a freshening composition in fluid communication with a membrane. The composition is substantially free of a surfactant and has from 0.5% to 20% of a volatile aldehyde mixture, by weight of the composition. The volatile aldehyde mixture includes a C5 to C8 unbranched unsubstituted linear alkenal and a C9 to C14 unbranched unsubstituted linear alkenal. A weight ratio of the C5 to C8 unbranched unsubstituted linear alkenal to the C9 to C14 unbranched unsubstituted linear alkenal is from 3:1 to 1:3.Type: ApplicationFiled: October 7, 2020Publication date: April 15, 2021Inventors: Yoshiki ISHIDA, Gaurav SAINI, Rahul VYAS, Garima CHAUHAN
-
Publication number: 20210106711Abstract: Disclosed herein are embodiments of filtration systems and iron oxide nanowire-based filter meshes that can capture and inactivate pathogens in air. The filter meshes can include a porous lattice of iron metal and iron oxide nanowires radiating from the porous lattice of iron metal. The iron oxide nanowires radiating from the porous lattice of iron metal can be created by processing the filter mesh using the disclosed method. Pathogens can be inactivated by passing a sample containing the pathogens through the filter mesh and inactivating at least a portion of the pathogens as the sample passes through the filter mesh.Type: ApplicationFiled: April 18, 2019Publication date: April 15, 2021Inventors: Weining Wang, Dawei Wang, Ping Xu, Bin Zhu
-
Publication number: 20210106712Abstract: A charging structure and an aroma diffuser suitable for a home furnishing small household electrical appliance. The appliance has a chassis and circuit, with a contact thimble arranged on the chassis and penetrating to a lower surface of the chassis. The contact thimble is connected to the circuit. An electrical connection component has a connector and a wire for connecting the connector. The wire is used for accessing a power source. The connector is electrically connected with the thimble when it is abutted with the contact thimble. A magnetic component has a first magnetic member disposed on the chassis and a second magnetic member disposed on the connector. The first magnetic member and second magnetic member are attracted to each other to abut the connector with the contact thimble. A horizontal projection of the chassis covers a horizontal projection of the connector.Type: ApplicationFiled: December 27, 2019Publication date: April 15, 2021Inventor: Andy LEE
-
Publication number: 20210106713Abstract: A hand wash cleaning and environmental purification diffuser includes tank cover covered on a slot of a water tank in a bottom shell, a diffusing cover assembled to an opening of the bottom shell to shield the tank cover, an air flow channel formed in the oscillation space in the water tank and shaped like a tubular bulge so that when the diffuser is dumped, the liquid in the water tank is less likely to seep directly into the interior of the diffuser or the environment, two oscillators mounted in the oscillation space in the water tank and respectively coated with a layer of acid and alkali resistant coating, users can add safe cleaning liquids such as alkaline ionized water to the oscillation space and atomize into a cleaning mist, which can be used as deodorization and sterilization for hand cleaning, disinfection and environmental purification, and is safe to use.Type: ApplicationFiled: December 17, 2020Publication date: April 15, 2021Inventor: Ming Jen HSIAO
-
Publication number: 20210106714Abstract: The present invention relates to a method for viral decontamination of a confined space, in particular of the air present in a confined space, based on application of a relative humidity of at least 50% created in said confined space, or incorporated at the level of a centralized air treatment system or an autonomous air purifier.Type: ApplicationFiled: December 18, 2018Publication date: April 15, 2021Inventors: Thi Lan HA, Sébastien RITOUX, Enric ROBINE
-
Publication number: 20210106715Abstract: An apparatus for treating air includes a housing with an air inlet and an air outlet, the housing enclosing an air treatment zone and an ozone removal zone, wherein the ozone removal zone is positioned downstream of the air treatment zone with respect to a flow direction of the air being treated, an ozone generator in the air treatment zone configured to generate ozone from the air, wherein the ozone generated by the ozone generator treats the air in the air treatment zone, catalyst in the ozone removal zone that removes at least a portion of the ozone generated the ozone generator, a particle matter (PM) filter positioned between the air treatment zone and the ozone removal zone, wherein the ozone generated by the ozone generator treats the PM filter, and an air mover positioned near the air outlet configured to draw the air through the air inlet.Type: ApplicationFiled: December 23, 2020Publication date: April 15, 2021Applicant: Bluezone IP Holding LLCInventors: Karen Benedek, Philip C. Carbone, Peter J. Loftus, David Hensel, Anna Cheimets, James Poon, Elizabeth Gillis, Warren J. Ellis, Charles Marble
-
Publication number: 20210106716Abstract: The present disclosure provides a biofragmentable sponge, comprising a three-dimensional porous scaffold formed by freeze-drying a mixture of about 5% to about 20% (w/w) of silk protein, about 5% to about 85% (w/w) of a water soluble synthetic polymer or a mixture of water soluble synthetic polymers, and about 10% to about 90% (w/w) of a polysaccharide.Type: ApplicationFiled: October 9, 2019Publication date: April 15, 2021Inventors: Jen-Chang YANG, Liang-Yu CHANG, Shih-Han HUNG, Hsin-Jen CHANG, Nai-Chia TENG
-
Publication number: 20210106717Abstract: The present embodiments provide systems and medical formulations suitable for delivering therapeutic powders to a target site. In one embodiment, the system comprises a delivery device, a first powder being formed of particles of a first material, and a second powder being formed of particles of a second material, wherein the second material is different than the first material. At least some of the particles of the first powder and the second powder are bound together to form bonded particles. The bonded particles are simultaneously delivered to the target site by the delivery device. In one embodiment, a medical formulation may comprise carbomer present in a range between about 60-80% by weight of the formulation, bentonite present in a range of between about 5-15% by weight of the formulation, and calcium carbonate present in a range of between about 10-30% by weight of the formulation.Type: ApplicationFiled: October 10, 2019Publication date: April 15, 2021Applicant: Cook Medical Technologies LLCInventors: Shaun D. Gittard, John C. Sigmon, JR., Christopher A. Carruthers
-
Publication number: 20210106718Abstract: A tissue adhesive composition comprises a biodegradable adhesive; nanoparticles; and a tissue regenerative agent. Methods of adhering tissue comprise applying a film of the tissue adhesive composition to a first surface of a first biological tissue; contacting a second surface of a second biological tissue with the first surface of the first biological tissue, wherein the film of the composition is positioned between and in contact with both the first surface and the second surface.Type: ApplicationFiled: October 13, 2020Publication date: April 15, 2021Inventors: YI HONG, Kytai NGUYEN, Philippe ZIMMERN, Jun LIAO
-
Publication number: 20210106719Abstract: The invention concerns a method of making a synthetic, biodegradable, bone graft comprising a three-dimensional porous structure; a formulation of constituents for use in said method; a synthetic, biodegradable bone graft produced by said method; and a method of surgery comprising use of said bone graft.Type: ApplicationFiled: March 21, 2019Publication date: April 15, 2021Applicant: Swansea UniversityInventor: Zhidao Xia
-
Publication number: 20210106720Abstract: The instant disclosure is directed to methods of improving bone-soft tissue healing using biocompatible electrospun polymer fibers. In one embodiment, a method may include locating a portion of a subject's bone, affixing a tendon or ligament to the bone using a hardware fixture, and placing a patch comprising at least one electrospun polymer fiber in physical communication with both the bone and the tendon or ligament. In some embodiments, the bone may be a humerus, and the tendon or ligament may be a supraspinatus tendon. In certain embodiments, the patch may comprise substantially parallel electrospun polymer fibers, and may be placed such that the fibers are also substantially parallel with the long axis of the tendon or ligament.Type: ApplicationFiled: December 22, 2020Publication date: April 15, 2021Applicant: NANOFIBER SOLUTIONS, LLCInventors: Jed K. JOHNSON, Devan OHST, Jason CHAKROFF, Brian COHEN, Anthony ROMEO
-
Publication number: 20210106721Abstract: Various aspects described herein relate to compositions comprising silk fibroin fragments with particular characteristics and/or properties as well as methods of making and using the same.Type: ApplicationFiled: October 27, 2020Publication date: April 15, 2021Applicant: Sofregen Medical, Inc.Inventors: Joseph E. Brown, Christopher P. Gulka, Anh Hoang-Lindsay
-
Publication number: 20210106722Abstract: Various aspects described herein relate to compositions comprising silk fibroin fragments with particular characteristics and/or properties as well as methods of making and using the same.Type: ApplicationFiled: October 27, 2020Publication date: April 15, 2021Applicant: Sofregen Medical, Inc.Inventors: Joseph E. Brown, Christopher P. Gulka, Anh Hoang-Lindsay
-
Publication number: 20210106723Abstract: Provided herein is a living bone graft including a biofabricated graft core including demineralized bone matrix and a carrier and a pre-vascularized shell at least partially enrobing the graft core, the pre-vascularized shell including isolated, intact adipose-derived microvessel fragments, mesenchymal stem cells, and collagen. The disclosed bone grafts include stromal cells that differentiate and microvessels that inosculate to provide a functional microvasculature, thereby approximating native bone repair as the graft matures in the patient. Also provided herein are methods of fabricating a bespoke, living, vascularized bone graft and methods of treating a segmental bone defect in a patient.Type: ApplicationFiled: October 9, 2020Publication date: April 15, 2021Inventors: James B. Hoying, Sarah Moss
-
Publication number: 20210106724Abstract: A method includes covering or contacting a portion of a recurrent laryngeal nerve of a subject with a shield including extraembryonic tissue. The covering occurs during a neck or reconstructive surgery of the subject.Type: ApplicationFiled: December 1, 2020Publication date: April 15, 2021Inventor: James Glenn Norman